Elizabeth Epstein
Cardiovascular Disease · la Jolla, CANPI 1265991376
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 33.7% of the total.
Across 100 payments — averaging $31.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Amgen$359
- Abbott$295
- Kestra Medical Technology Services, Inc.$245
- Novartis$206
- Esperion Therapeutics, Inc.$171
- plus $790 from 16 others
What the payments were for
- Food & beverage$2,84491%
- Education$2709%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $1,049 |
| Amgen | 19 | $359 |
| Abbott | 2 | $295 |
| Kestra Medical Technology Services, Inc. | 7 | $245 |
| Novartis | 10 | $206 |
| Esperion Therapeutics, Inc. | 3 | $171 |
| Regeneron Healthcare Solutions, Inc. | 6 | $145 |
| Boston Scientific | 3 | $92 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $86 |
| Cvrx, Inc. | 3 | $84 |
| Medtronic | 2 | $70 |
| Irhythm Technologies, Inc. | 3 | $62 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $48 |
| Philips North America LLC | 2 | $38 |
| Edwards Lifesciences | 1 | $31 |
| Dexcom, Inc. | 1 | $27 |
| Novo Nordisk | 1 | $24 |
| Baxter Healthcare | 1 | $18 |
| Viiv Healthcare Company | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Abiomed | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,115 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $33,824 |
| Repatha SureclickEvolocumab | 25 | $27,379 |
| Ezetimibe | 87 | $2,887 |
| Rosuvastatin Calcium | 52 | $807 |
| ClopidogrelClopidogrel Bisulfate | 18 | $306 |
| Carvedilol | 22 | $250 |
| Metoprolol Succinate | 12 | $182 |
| Spironolactone | 13 | $164 |
| Amlodipine Besylate | 23 | $150 |
| Losartan Potassium | 11 | $121 |
| Atorvastatin Calcium | 15 | $114 |
| Lisinopril | 12 | $57 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in la Jolla
- Eric Topolla Jolla$2.2M
- Pam Taubla Jolla$1.2M
- Douglas Gibsonla Jolla$727K
- Douglas Triffonla Jolla$176K
- Judith Swainla Jolla$151K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Cathleen Bairey-MerzLos Angeles$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.